Julie V Decock

List of Publications by Year
in descending order

50 papers	2,011 citations	304743 22 h-index	265206 42 g-index
53 all docs	53 docs citations	53 times ranked	3398 citing authors

#	Article	IF	Citations
1	Targeting of lactate dehydrogenase C dysregulates the cell cycle and sensitizes breast cancer cells to DNA damage response targeted therapy. Molecular Oncology, 2022, 16, 885-903.	4.6	11
2	Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications. Nature Communications, 2022, 13, 946.	12.8	30
3	Ancestry-associated transcriptomic profiles of breast cancer in patients of African, Arab, and European ancestry. Npj Breast Cancer, 2021, 7, 10.	5.2	11
4	Transcription Factors: The Fulcrum Between Cell Development and Carcinogenesis. Frontiers in Oncology, 2021, 11, 681377.	2.8	25
5	Cancer testis antigen PRAME: An antiâ€cancer target with immunomodulatory potential. Journal of Cellular and Molecular Medicine, 2021, 25, 10376-10388.	3.6	13
6	Immune checkpoints in the tumor microenvironment. Seminars in Cancer Biology, 2020, 65, 1-12.	9.6	146
7	Lactate Metabolism and Immune Modulation in Breast Cancer: A Focused Review on Triple Negative Breast Tumors. Frontiers in Oncology, 2020, 10, 598626.	2.8	26
8	Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response. , 2020, 8, e000617.		57
9	Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy. Cancer Immunology, Immunotherapy, 2020, 69, 449-463.	4.2	20
10	Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects. Frontiers in Oncology, 2020, 10, 600573.	2.8	100
11	579â€...Lactate dehydrogenase C-associated molecular networks predict enhanced tumor growth and impaired immune response in breast cancer. , 2020, , .		0
12	Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?. Cancers, 2019, 11, 984.	3.7	78
13	The Obesity Paradox in Cancer, Tumor Immunology, and Immunotherapy: Potential Therapeutic Implications in Triple Negative Breast Cancer. Frontiers in Immunology, 2019, 10, 1940.	4.8	66
14	PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer. Journal of Translational Medicine, 2019, 17, 9.	4.4	43
15	NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives. Frontiers in Immunology, 2018, 9, 947.	4.8	261
16	Loss of MMP-8 in ductal carcinoma in situ (DCIS)-associated myoepithelial cells contributes to tumour promotion through altered adhesive and proteolytic function. Breast Cancer Research, 2017, 19, 33.	5.0	29
17	Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications. International Journal of Molecular Sciences, 2017, 18, 2229.	4.1	105
18	PRAME, cell migration and invasion of triple negative breast cancer cells. Annals of Oncology, 2017, 28, xi26.	1.2	1

#	Article	IF	Citations
19	The MAPK hypothesis: immune-regulatory effects of MAPK-pathway genetic dysregulations and implications for breast cancer immunotherapy. Emerging Topics in Life Sciences, 2017, 1, 429-445.	2.6	45
20	A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification. F1000Research, 2017, 6, 296.	1.6	14
21	A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification. F1000Research, 2017, 6, 296.	1.6	14
22	Cancer testis antigen expression in triple negative breast cancer: Candidate targets for cancer immunotherapy?. , 2015, 3, P381.		0
23	Metalloproteinaseâ€dependent and â€independent processes contribute to inhibition of breast cancer cell migration, angiogenesis and liver metastasis by a disintegrin and metalloproteinase with thrombospondin motifsâ€15. International Journal of Cancer, 2015, 136, E14-26.	5.1	46
24	Pleiotropic functions of the tumor- and metastasis-suppressing matrix metalloproteinase-8 in mammary cancer in MMTV-PyMT transgenic mice. Breast Cancer Research, 2015, 17, 38.	5.0	35
25	Metalloproteinase-dependent And -independent Processes Contribute To Inhibition Of Breast Cancer Cell Migration, Angiogenesis And Liver Metastasis By A Disintegrin And Metalloproteinase With Thrombospondin Motifs-15.. , 2014, , .		0
26	Matrix metalloproteinases: a dual role in breast cancer?. Breast Cancer Management, 2013, 2, 353-356.	0.2	1
27	Selenium Biomarkers in Prostate Cancer Cell Lines and Influence of Selenium on Invasive Potential of PC3 Cells. Frontiers in Oncology, 2013, 3, 239.	2.8	13
28	Matrix Metalloproteinase 8 (Collagenase 2) Induces the Expression of Interleukins 6 and 8 in Breast Cancer Cells. Journal of Biological Chemistry, 2013, 288, 16282-16294.	3.4	52
29	TGF-Î²-Elicited Induction of Tissue Inhibitor of Metalloproteinases (TIMP)-3 Expression in Fibroblasts Involves Complex Interplay between Smad3, p38Î±, and ERK1/2. PLoS ONE, 2013, 8, e57474.	2.5	55
30	Short-Term Prognostic Index for Breast Cancer: NPI or Lpi. Pathology Research International, 2011, 2011, 1-7.	1.4	4
31	The roles of ADAMTS metalloproteinases in tumorigenesis and metastasis. Frontiers in Bioscience - Landmark, 2011, 16, 1861.	3.0	83
32	Matrix metalloproteinases: protective roles in cancer. Journal of Cellular and Molecular Medicine, 2011, 15, 1254-1265.	3.6	160
33	ADAMTS15 metalloproteinase inhibits breast cancer cell migration. Breast Cancer Research, 2010, 12, .	5.0	5
34	Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors. Breast Cancer Research and Treatment, 2009, 115, 349-358.	2.5	18
35	Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive. Breast Cancer Research and Treatment, 2009, 113, 181-187.	2.5	76
36	Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer. Clinical Genetics, 2008, 73, 197-211.	2.0	50

#	Article	IF	Citations
37	Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer. Breast Cancer Research and Treatment, 2008, 110, 153-159.	2.5	11
38	Plasma MMP1 and MMP8 expression in breast cancer: Protective role of MMP8 against lymph node metastasis. BMC Cancer, 2008, 8, 77.	2.6	55
39	Association of MMP8 gene variation with breast cancer prognosis. Breast Cancer Research, 2008, 10, .	5.0	2
40	Plasma MMP1, MMP8 and MMP13 expression in breast cancer: protective role of MMP8 against lymph node metastasis. Breast Cancer Research, 2008, 10, .	5.0	2
41	Cathepsin B, cathepsin H, cathepsin X and cystatin C in sera of patients with early-stage and inflammatory breast cancer. International Journal of Biological Markers, 2008, 23, 161-168.	1.8	36
42	Association ofMatrix Metalloproteinase-8Gene Variation with Breast Cancer Prognosis. Cancer Research, 2007, 67, 10214-10221.	0.9	85
43	Matrix Metalloproteinase Expression Patterns in Luminal A Type Breast Carcinomas. Disease Markers, 2007, 23, 189-196.	1.3	19
44	Loss of nuclear BRCA1 protein staining in normal tissue cells derived from BRCA1 and BRCA2 mutation carriers. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007, 619, 104-112.	1.0	6
45	P52 The axillary lymph node status (ALNS) of breast cancers by combined ER, PR and HER-2 expression: Triple positive tumours are more likely lymph node positive. Breast, 2007, 16, S27.	2.2	0
46	P54 Triple positive (ER+/PR+/HER-2+) breast carcinomas occur at a younger age than all other ER/PR/HER-2 breast cancer phenotypes. Breast, 2007, 16, S27-S28.	2.2	35
47	How Accurate Is the Antiprimer Quenching-Based Real-Time PCR for Detection of Her2/neu in Clinical Cancer Samples?. Clinical Chemistry, 2006, 52, 1438-1439.	3.2	0
48	Proteases and metastasis: clinical relevance nowadays?. Current Opinion in Oncology, 2005, 17, 545-550.	2.4	33
49	Plasma Gelatinase Levels in Patients with Primary Breast Cancer in Relation to Axillary Lymph Node Status, Her2/neu Expression and other Clinicopathological Variables. Clinical and Experimental Metastasis, 2005, 22, 495-502.	3.3	17
50	Clinical relevance of plasma matrix metalloproteinase-2 levels in primary invasive breast cancer. Journal of Clinical Oncology, 2005, 23, 9680-9680.	1.6	0